Literature DB >> 2466872

Chronic relapsing experimental allergic encephalomyelitis in SJL mice following the adoptive transfer of an epitope-specific T cell line.

R J Fallis1, C S Raine, D E McFarlin.   

Abstract

Chronic relapsing experimental allergic encephalomyelitis (CREAE) was induced in SJL mice following the adoptive transfer of a T cell line derived from mice immunized with a synthetic peptide corresponding to residues 89-100 of the guinea pig myelin basic protein (MBP) molecule. This cell line proliferated to both the peptide and MBP and induced CREAE characterized by a series of relapses with eventual stabilization. Central nervous system (CNS) inflammation and demyelination were prominent neuropathologic features of both the acute and relapsing phase of the disease. The chronic phase was characterized by CNS lesions containing chronically demyelinated fibers with remyelination and some fiber drop-out, but little inflammation. The induction of CREAE in SJL mice by a cell line specific for residues 89-100 demonstrates that T cell recognition of this epitope is required for successful disease induction in this strain of mouse.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2466872     DOI: 10.1016/0165-5728(89)90039-8

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  11 in total

Review 1.  Molecular mechanisms involved in the etiology and pathogenesis of autoimmune diseases.

Authors:  M Trucco
Journal:  Clin Investig       Date:  1992-09

2.  Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes.

Authors:  S D Sharma; B Nag; X M Su; D Green; E Spack; B R Clark; S Sriram
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

Review 3.  Stage-specific immune dysregulation in multiple sclerosis.

Authors:  Benjamin M Segal
Journal:  J Interferon Cytokine Res       Date:  2014-08       Impact factor: 2.607

4.  Antigen-presenting innate lymphoid cells orchestrate neuroinflammation.

Authors:  Arthi Shanmugavadivu; Tommy Regen; John B Grigg; Christopher N Parkhurst; Anees Ahmed; Ann M Joseph; Michael Mazzucco; Konrad Gronke; Andreas Diefenbach; Gerard Eberl; Timothy Vartanian; Ari Waisman; Gregory F Sonnenberg
Journal:  Nature       Date:  2021-12-01       Impact factor: 69.504

5.  Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein.

Authors:  E A Elliott; H I McFarland; S H Nye; R Cofiell; T M Wilson; J A Wilkins; S P Squinto; L A Matis; J P Mueller
Journal:  J Clin Invest       Date:  1996-10-01       Impact factor: 14.808

Review 6.  Encephalitogenic and Regulatory CD8 T Cells in Multiple Sclerosis and Its Animal Models.

Authors:  Taryn E Mockus; Ashley Munie; Jeffrey R Atkinson; Benjamin M Segal
Journal:  J Immunol       Date:  2021-01-01       Impact factor: 5.422

7.  Viral infection of transgenic mice expressing a viral protein in oligodendrocytes leads to chronic central nervous system autoimmune disease.

Authors:  C F Evans; M S Horwitz; M V Hobbs; M B Oldstone
Journal:  J Exp Med       Date:  1996-12-01       Impact factor: 14.307

8.  In vivo survival of viral antigen-specific T cells that induce experimental autoimmune encephalomyelitis.

Authors:  R L Ufret-Vincenty; L Quigley; N Tresser; S H Pak; A Gado; S Hausmann; K W Wucherpfennig; S Brocke
Journal:  J Exp Med       Date:  1998-11-02       Impact factor: 14.307

Review 9.  The Diversity of Encephalitogenic CD4+ T Cells in Multiple Sclerosis and Its Animal Models.

Authors:  Benjamin M Segal
Journal:  J Clin Med       Date:  2019-01-19       Impact factor: 4.241

Review 10.  Two models of multiple sclerosis: experimental allergic encephalomyelitis (EAE) and Theiler's murine encephalomyelitis virus (TMEV) infection. A pathological and immunological comparison.

Authors:  M C Dal Canto; R W Melvold; B S Kim; S D Miller
Journal:  Microsc Res Tech       Date:  1995-10-15       Impact factor: 2.769

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.